Wall Street brokerages predict that Champions Oncology Inc (NASDAQ:CSBR) will announce $6.35 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for Champions Oncology’s earnings. The highest sales estimate is $6.50 million and the lowest is $6.20 million. Champions Oncology reported sales of $5.20 million during the same quarter last year, which indicates a positive year over year growth rate of 22.1%. The company is expected to issue its next quarterly earnings results on Thursday, December 6th.
On average, analysts expect that Champions Oncology will report full-year sales of $25.31 million for the current financial year, with estimates ranging from $25.23 million to $25.40 million. For the next financial year, analysts expect that the business will report sales of $31.00 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Champions Oncology.
Champions Oncology (NASDAQ:CSBR) last announced its quarterly earnings data on Thursday, September 13th. The biotechnology company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.03. The firm had revenue of $6.23 million for the quarter, compared to analyst estimates of $5.85 million. Champions Oncology had a negative net margin of 1.63% and a negative return on equity of 97.02%.
Several research firms have recently commented on CSBR. Janney Montgomery Scott began coverage on shares of Champions Oncology in a research report on Monday, July 9th. They set a “buy” rating for the company. Craig Hallum began coverage on shares of Champions Oncology in a research report on Tuesday, July 17th. They set a “buy” rating and a $12.00 target price for the company. Finally, Zacks Investment Research raised shares of Champions Oncology from a “hold” rating to a “strong-buy” rating and set a $12.00 target price for the company in a research report on Monday, September 17th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $11.33.
In other Champions Oncology news, Director Daniel Newman Mendelson sold 8,333 shares of the company’s stock in a transaction dated Thursday, September 20th. The shares were sold at an average price of $13.02, for a total value of $108,495.66. Following the completion of the sale, the director now directly owns 62,500 shares of the company’s stock, valued at approximately $813,750. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Joel Ackerman sold 22,535 shares of the company’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $17.02, for a total transaction of $383,545.70. Following the completion of the sale, the director now directly owns 1,021,731 shares of the company’s stock, valued at $17,389,861.62. The disclosure for this sale can be found here. Insiders own 44.30% of the company’s stock.
A number of hedge funds have recently modified their holdings of the business. Bank of Montreal Can bought a new stake in Champions Oncology in the 3rd quarter worth about $250,000. Tocqueville Asset Management L.P. bought a new stake in Champions Oncology in the 2nd quarter worth about $729,000. Renaissance Technologies LLC grew its position in Champions Oncology by 63.3% in the 2nd quarter. Renaissance Technologies LLC now owns 100,600 shares of the biotechnology company’s stock worth $638,000 after purchasing an additional 39,000 shares in the last quarter. BlackRock Inc. bought a new stake in Champions Oncology in the 2nd quarter worth about $104,000. Finally, Perkins Capital Management Inc. bought a new stake in Champions Oncology in the 2nd quarter worth about $653,000. 38.52% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ:CSBR traded up $0.46 during midday trading on Friday, hitting $12.39. 181,409 shares of the company’s stock were exchanged, compared to its average volume of 110,894. The company has a debt-to-equity ratio of 0.23, a current ratio of 0.73 and a quick ratio of 0.73. The company has a market cap of $195.04 million, a PE ratio of -88.50 and a beta of -0.18. Champions Oncology has a 12 month low of $3.05 and a 12 month high of $17.90.
About Champions Oncology
Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.
Read More: What Factors Can Affect Return on Equity?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.